38 results about "Deoxyglucose" patented technology

The invention discloses light-colored baked barley rich in wheat fragrance as well as a preparation method and application thereof, and belongs to the technical field of wheat making. According to the technical scheme, the method comprises the following steps: regulating and controlling the content of wheat fragrance substance furanone of the baked barley by controlling the content of 1-deoxyglucaldehyde ketone of the barley serving as a raw material, and regulating and controlling the color L * value of the baked barley by controlling the content of 3-deoxyglucaldehyde ketone of the barley serving as the raw material, so as to prepare the light-color baked barley with rich wheat fragrance. The preparation method is applied to the aspect of wheat tea drinks, the problem that light-colored baked barley with rich wheat fragrance and soft taste cannot be prepared by an existing baked barley preparation process is solved, and the light-colored baked barley with rich wheat fragrance and soft taste is prepared.

A dendrimer that includes: (a) a central core; and (b)(i) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core; or (b)(ii) at least one trehalose-surfaced branching units conjugated to the central core; or (b)(iii) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core and at least one trehalose-surfaced branching units conjugated to the central core.

The invention discloses an NKT cell, a culture medium and a culture method thereof, and relates to the technical field of cell culture, the NKT cell comprises a basal culture medium, a cell factor combination, a plant extract compound, a metabolism regulator and an antioxidant; wherein the plant extract compound is prepared from astragalus polysaccharide, ganoderic acid, tea polyphenol, asiaticoside and notoginsenoside R1, and the mass ratio of the astragalus polysaccharide to the ganoderic acid to the tea polyphenol to the asiaticoside to the notoginsenoside R1 is (3 to 5) to (1 to 2) to 1 to (0.5 to 1) to (0.5 to 1). According to the NKT cell, the culture medium and the culture method of the NKT cell, through the synergistic effect of the six-membered plant extract compound, the expression of cyclin is promoted, the G1 / S phase conversion is accelerated, and the cell amplification amount is remarkably increased; the ratio of plant extracts and high astragalus polysaccharide are dynamically adjusted, so that cell proliferation and induced differentiation of high ganoderic acid are promoted, cells are forced to turn to efficient-productivity oxidative phosphorylation metabolism in cooperation with 2-deoxyglucose, and the cell multiplication time is shortened.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

The present invention relates to a composition comprising, as active ingredients: (1) a biguanide-based compound or a pharmaceutically acceptable salt thereof; (2) 2-deoxy-D-glucose; and (3) inositol hexaphosphate or a pharmaceutically acceptable salt thereof, inositol, or a mixture thereof. The composition according to the present invention exhibits a synergistic anticancer effect by appropriately combining specific drugs having a problem that needs to be used in a large amount, thereby making it possible to kill cancer cells in a small amount and effectively treat the cancer. Furthermore, the composition of the present invention may kill only cancer cells without side effects by exhibiting a specific toxic effect on cancer cells without showing toxicity on normal cells and thus be usefully used as an anticancer agent and for preventing or improving cancer.

The invention relates to the technical field of CAR-T cell culture, in particular to a CAR-T cell culture medium and application thereof. The CAR-T cell culture medium is one of CAR-T cell culture mediums in different culture stages: a T cell activation culture medium in a T cell activation stage, which comprises 2-Deoxyglucose; or a CAR-T cell culture medium in a continuous culture stage, wherein the CAR-T cell culture medium comprises 2-Deoxyglucose; or a CAR-T cell culture medium in a culture later stage, wherein the CAR-T cell culture medium comprises 2-Deoxyglucose. Compared with CAR-T cells cultured by a CAR-T cell culture medium without 2-Deoxyglucose, the CAR-T cell culture medium has the advantages that the proportion of the juvenile CAR-T cells is increased, and the anti-tumor effect is enhanced.

The present invention relates to a novel 5-dehydro-2-deoxygluconokinase variant and a method of producing 5′-inosinic acid using the same. The 5-dehydro-2-deoxygluconokinase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting 5-dehydro-2-deoxygluconokinase to change the activity of the protein, and a recombinant microorganism comprising the 5-dehydro-2-deoxygluconokinase variant is capable of efficiently producing 5′-inosinic acid.

The present invention provides a method for producing a mesenchymal stem cell culture, a mesenchymal stem cell culture, a pharmaceutical composition comprising the mesenchymal stem cell culture, and a method for producing a population of mesenchymal cells. The method for producing a mesenchymal stem cell culture comprises the steps of (a) culturing a tissue-derived sample containing a population of mesenchymal stem cells under serum-starvation conditions or in a medium containing 2-deoxy-D-glucose (2-DG), thereby isolating a culture of mesenchymal stem cells that survive the serum-starvation conditions or the 2-DG-containing medium conditions, wherein the population of mesenchymal stem cells is not exposed to proliferation conditions between collection of the tissue-derived sample from an individual and culturing under serum-starvation conditions or in a medium containing 2-DG.

Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The invention discloses clinical application of a metabolic immune and Dai medicine composition in treatment of cancer, the composition comprises: a composition for regulating and controlling tumor cell metabolism, including 2-deoxy-D-glucose, a glycolysis inhibitor, an oxidative phosphorylation inhibitor, a pyruvate dehydrogenase kinase inhibitor, a polyphenol compound and green tea polyphenol; at least one immunomodulator; at least one chemotherapeutic agent; the clinical application of the metabolic immune combined Dai medicine for treating the cancer is realized through action mechanisms in multiple aspects, including influence on the metabolic activity of tumor cells, enhancement of the effect of an immune system, enhancement of the effect of a chemotherapy medicine and leveling of four towers and five components, so that toxin is eliminated, qi and blood are straightened out, resistance is enhanced, and the clinical application of the metabolic immune combined Dai medicine for treating the cancer is realized. The functions of four towers and five components are balanced and coordinated, so that the aim of treating cancers is fulfilled.

The invention discloses an epilepsy focus detection method based on magnetic resonance imaging. The epilepsy focus detection method comprises the steps that MRI data and < 18 > F fluorescence deoxyglucose PET / CT scanning data of a patient before an operation are collected; processing the MRI data and the PET data; carrying out statistical analysis on the PET image, comparing a standard deviation with a normal database, and generating a QPET image; carrying out QPET-MAP (Quality Point of Emission Tomography Whether the cut QPET-MAP + area is mainly in the FCD type I or not is determined through postoperative pathological examination; and performing registration on the preoperative MRI and the postoperative MRI by using SPM12 software, and determining the excision integrity of the QPET-MAP + region. The QPET provides functional imaging data, and metabolic changes related to epilepsy are identified through quantitative analysis of PET scanning; the MAP provides structural imaging data, identifying a potential FCD by automated analysis of the MRI data; the detection rate of the FCD of the MRI negative epileptic is improved through the MAP. The detection sensitivity is improved, the specificity is also increased, and the epileptic focus is more accurately positioned. According to the invention, surgeons can be helped to more accurately position and cut epileptic lesions, and the operation effect is improved.

The invention discloses a metabolic antagonist solution which is obtained by dissolving a metabolic antagonist in water, the metabolic antagonist is L-2-enol hexolactone and / or 2-deoxy-D-glucose, and the invention also discloses an application of the metabolic antagonist solution in storage of crude rosin. The metabolism antagonist solution provided by the invention aims at glycolysis and energy metabolism of impurities such as pine needles and barks, and discoloration and degradation of the crude rosin in the storage process are blocked from the source; the L-2-enol hexanoic acid lactone oxidation product enters cells through glucose transporters such as GLUT1 / 3 / 4, competes for binding sites with glucose, and interferes with glycolysis and energy metabolism of impurities such as pine needles and barks; the 2-deoxy-D-glucose has a pyranoid ring conformation highly similar to that of glucose, is acidified into 2-deoxyglucose-6-phosphoric acid by hexokinase, and hijacks a glycolytic pathway, resulting in metabolic blocking and energy depletion.

The invention discloses application of a disulfide death inhibitor in a medicine and the medicine, and relates to the technical field of medicines, in particular to application of the disulfide death inhibitor in preparation of a medicine for treating hepatic ischemia-reperfusion injury, and the disulfide death inhibitor is 2-deoxy-D-glucose or tris (2-carboxyethyl) phosphine. It is found for the first time that the disulfide death inhibitor (2-deoxy-D-glucose and tris (2-carboxyethyl) phosphine) has a remarkable treatment effect on the hepatic ischemia reperfusion injury, and the 2-deoxy-D-glucose and the tris (2-carboxyethyl) phosphine can effectively relieve sulfide stress in hepatic cells and cytoskeleton shrinkage caused by hepatic ischemia; further, the disulfide death of liver cells is reduced, and the liver injury recovery is favorably promoted; therefore, the disulfur death inhibitor is applied to preparation of the medicine for treating the hepatic ischemia reperfusion injury, and a new method is provided for clinical prevention and treatment of the hepatic ischemia reperfusion injury.

The present invention relates to a novel 5-dehydro-2-deoxygluconokinase variant and a method of producing 5′-inosinic acid using the same. The 5-dehydro-2-deoxygluconokinase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting 5-dehydro-2-deoxygluconokinase to change the activity of the protein, and a recombinant microorganism comprising the 5-dehydro-2-deoxygluconokinase variant is capable of efficiently producing 5′-inosinic acid.

The invention discloses a metabolic composition for diagnosing rheumatoid arthritis and application of the metabolic composition, and belongs to the technical field of biomedicine. The metabolic composition is prepared from imidazole-4-acetic acid, ergothioneine, N-acetyl-L-methionine, 2-ketone-3-deoxy-D-gluconic acid, 1-methyl nicotinamide and dehydroepiandrosterone sulfate, and the metabolic composition is prepared from the following raw materials in parts by weight: 20-30% of L-methionine, 20-30% of L-methionine The characteristic combination formed by the six metabolites shows obvious difference in RA patients, RA and non-RA groups can be effectively distinguished, and the overall diagnosis accuracy of RA is obviously improved. The discovery provides powerful supplement for early and accurate recognition of RA, and is particularly suitable for complex cases with negative traditional indexes but highly suspected RA in clinic.

Provided herein are methods and pharmaceutical compositions for preventing or reducing frequency or severity of convulsions or seizures, particularly epileptic seizures by administration of a therapeutically effective amount of 2-deoxy-D-glucose (2-DG) in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones. Also provided are methods and pharmaceutical compositions for reducing severity and progression of traumatic brain injury and deleterious sequelae resulting therefrom in an animal by administration of a therapeutically effective amount of 2-DG in combination with a therapeutically effective amount of beta-hydroxybutyrate, or 2-DG with other ketones or metabolic intermediates that increase brain ketones.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

Provided are a method for producing a mesenchymal stem cell culture, a mesenchymal stem cell culture, a pharmaceutical composition containing a mesenchymal stem cell culture, and a method for producing a population of mesenchymal cells. This method for producing a mesenchymal stem cell culture includes a step (a) for culturing a tissue-derived sample containing a population of mesenchymal stem cells under serum starvation conditions or 2-deoxy-D-glucose (2-DG)-containing culture medium conditions to thereby separate a culture of mesenchymal stem cells that survived the serum starvation conditions or 2-DG-containing culture medium conditions. The population of mesenchymal stem cells is not exposed to growth conditions from after collection of the tissue-derived sample from an individual until culturing is performed under serum starvation conditions or 2-DG-containing culture medium conditions.

Provided are compositions and methods for producing dihydrofurans by way of glycosyl hydrolases that can dehydrate 2-keto-3-deoxy-gluconate (KDG) to K4. Provided are also compositions and methods for further processing K4 to create HMFA (5-hydroxymethyl-2-furoic acid) and / or FDCA (2,5-furan dicarboxylic acid).

The utility model relates to the technical field of deoxidized glucose injection bottle plugs, in particular to deoxidized glucose injection bottle plug press sealing equipment which comprises a supporting assembly and a box body, the box body is arranged at the upper end of the supporting assembly, a box door is movably installed on one side of the box body, a fixing cover is arranged at the upper end of the box body, and a press sealing mechanism is arranged at the upper end of the box body. A first transmission rod is arranged at the output end of the hydraulic assembly; a sliding plate is arranged at one end of the first transmission rod; a press-sealing assembly is arranged at the lower end of the sliding plate; a second transmission rod is arranged in the press-sealing assembly; an adjusting mechanism is arranged in the box body, a first limiting sleeve is arranged in the adjusting mechanism, a first threaded rod is arranged on the first limiting sleeve, a first sliding sleeve is arranged on the first threaded rod, a first limiting rod is arranged on one side of the first sliding sleeve, and a first turbine is arranged at the bottom end of the first threaded rod.

The present invention provides a hexokinase inhibitor, a hexokinase inhibitor ruthenium complex and its application in the preparation of anti-tumor drugs, belonging to the technical field of anti-tumor drugs. The present invention uses 2-deoxy-d-ribose as a parent nucleus to replace the 2-deoxy-D-glucose structure for modification. The present invention adopts deoxyribose and amino acids, which are endogenous substances in the human body, to construct a hexokinase inhibitor with a structure shown in Formula I with low drug toxicity and high anti-tumor biological activity. At the same time, the present invention introduces the concept of ruthenium complex on the basis of the hexokinase inhibitor with a structure shown in Formula I, and the obtained hexokinase inhibitor ruthenium complex can undergo molecular self-assembly in an aqueous solution to form self-assembled nanoparticles, thereby improving the targeting of tumors. At the same time, the hexokinase inhibitor ruthenium complex can act on the aerobic respiration and glycolysis pathways of tumor cells, effectively inhibit the energy metabolism pathways of tumor cells, and further enhance the anti-tumor activity.

The invention belongs to the technical field of microorganisms, and discloses a Saccharomyces cerevisiae DG-11 strain with low acetic acid yield, and the preservation number of the Saccharomyces cerevisiae DG-11 strain is CCTCC (China Center for Type Culture Collection) M 20251925. The strain is obtained by combining ARTP mutagenesis with 2-deoxyglucose (2-DG) resistance screening, and has the following characteristics that in simulated fruit juice fermentation, the yield of acetic acid is remarkably reduced compared with that of an original strain RV002; in the metabolic pathway, the activities of pyruvate decarboxylase (Pdc) and acetaldehyde dehydrogenase (Ald) are inhibited, and the activity of ethanol dehydrogenase (Adh) is enhanced, so that carbon metabolism is inclined to ethanol synthesis; meanwhile, the strain has excellent ethanol, high glucose and pH tolerance, and is stable in hereditary character. In addition, the content of acetic esters in the DG-11 fermentation liquor is reduced, and the content of part of ethyl esters and higher alcohols is increased, so that the flower and fruit aroma characteristics are favorably formed. The saccharomyces cerevisiae strain with excellent performance and low acetic acid yield is provided for fruit wine brewing, and the saccharomyces cerevisiae strain has important industrial application value.

A dendrimer that includes: (a) a central core; and (b)(i) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core; or (b)(ii) at least one trehalose-surfaced branching units conjugated to the central core; or (b)(iii) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core and at least one trehalose-surfaced branching units conjugated to the central core.

Provided herein is a dendrimer complex comprising a 2-deoxy glucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The application discloses a combined drug for treating tumors; aims to provide a treatment scheme for targeting transport of a chemotherapeutic drug and a metabolic drug, activating a tumor microenvironment, and treating tumor patients by combining chemotherapy, metabolic therapy and immunotherapy; and the technical key point is that an immune-activated biomimetic nanovesicle is used to load a chemotherapeutic drug, doxorubicin hydrochloride (DOX), and a sugar metabolism inhibitor, 2-deoxy-D-glucose (2-DG); wherein: the activated biomimetic nanovesicle highly expresses PD1 molecules, can competitively interact with PD-L1, and can release the inhibition on immune cells; the DOX is a chemotherapeutic drug; the 2-DG is a glycolysis inhibitor, and can inhibit the glycolysis process in cells; and the application belongs to the field of medical biotechnology.

A dendritic polymer comprising: (a) a central core; and (b)(i) at least one 2-deoxyglucose surface branching unit conjugated to the central core; or (b)(ii) at least one trehalose surface branching unit conjugated to the central core; or (b)(iii) at least one 2-deoxyglucose surface branching unit conjugated to the central core and at least one trehalose surface branching unit conjugated to the central core.

This invention provides a fluoro-18 labeled p-aminophenylboronic acid, its preparation method, and its application. The fluoro-18 labeled p-aminophenylboronic acid is N-(4-phenylboronic acid)-2-D-fluorodeoxyglucosamine (4-N-[ 18 [F]FDGly-PBA). Among them, fluoro-18 labeled fluorodeoxyglucose can be used for tumor imaging, and p-aminophenylboronic acid can be used for BNCT treatment. Therefore, the fluoro-18 labeled p-aminophenylboronic acid provided by the present invention is a novel dual-targeted diagnostic and therapeutic imaging agent that can be used for tumor PET / CT imaging and BNCT treatment.

The present invention relates to a novel mutant of 5-dehydro-2-deoxyglucono kinase and a method for producing 5'-inosinic acid using the same. In the 5-dehydro-2-deoxyglucono kinase mutant, one or more amino acids in the amino acid sequence constituting 5-dehydro-2-deoxyglucono kinase are substituted, resulting in a change in the activity of the protein, and a recombinant microorganism containing the same can efficiently produce 5'-inosinic acid.

The invention relates to a KmRgt1 protein mutant. Compared with a wild type KmRgt1 protein, the KmRgt1 protein mutant has amino acid mutations of S344A, S345A, S348A, S350A, S756A and T754A; preferably, the amino acid sequence of the KmRgt1 protein mutant is as shown in SEQ ID NO: 1. On the basis of the mutant, an engineering strain capable of relieving the glucose inhibition effect can be obtained, the obtained engineering strain basically keeps the original glucose utilization capacity, and meanwhile, the utilization of non-glucose carbon sources such as xylose, glycerol, cane sugar and lactose is not inhibited by 2-deoxyglucose any more; therefore, co-utilization of mixed sugars such as glucose and xylose can be realized, and the method has great potential of producing high-added-value bio-based products by utilizing biomass such as lignocellulose.